Want to see JANX full AI Analyst Report?
JANX Stock Chart & Stats
$15.33
-$0.39(-2.48%)
At close: 4:00 PM EDT
$15.33
-$0.39(-2.48%)
Day’s Range― - ―
52-Week Range$12.12 - $35.34
Previous CloseN/A
Volume550.01K
Average Volume (3M)1.23M
Market Cap
$1.02B
Enterprise Value$16.79
Total Cash (Recent Filing)$970.91M
Total Debt (Recent Filing)$20.99M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Nov 10, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.64
Shares Outstanding61,136,772
10 Day Avg. Volume789,836
30 Day Avg. Volume1,233,816
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)0.89
Price to Sales (P/S)85.51
P/FCF Ratio-10.27
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$35.63Price Target Upside132.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.71
Revenue Forecast (FY)$31.62M
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetVery low leverage and a sizeable equity base provide durable financial flexibility to fund multi-year clinical programs and withstand trial delays. This capital structure reduces near-term refinancing risk and preserves optionality to advance pipeline without immediate heavy borrowing.
Top-line Momentum And Healthy Gross MarginSustained TTM revenue growth combined with high gross margins suggests strengthening partner interest and efficient program execution. Durable revenue momentum from collaborations can support ongoing R&D and validates elements of the technology platform beyond one-off receipts.
Differentiated Therapeutic PlatformA platform focused on tumor-activated engagers and masked antibodies targets improved tolerability and selective activation, providing a structural competitive advantage. Platform breadth across oncology and autoimmune indications raises the long-term probability of clinical and partnering successes.
Bears Say
Sustained Cash BurnPersistent negative operating and free cash flow indicates ongoing cash consumption to fund trials. Even with improvement versus prior year, continued burn requires external financing or partnerships, creating dilution risk and constraining long-term investment flexibility.
Deep Negative ProfitabilitySubstantial and persistent net losses reflect heavy R&D and SG&A spend typical for clinical-stage biotech. Profitability is distant, meaning the company must convert clinical progress into partnerships or approvals to materially change financial trajectory over the medium term.
Revenue & Funding Reliant On PartnershipsDependence on partner payments and milestone-triggered revenue makes cash flows binary and timing‑uncertain. Reliance on equity markets to finance operations risks dilution and links runway to external funding conditions rather than stable product sales.
Janux Therapeutics Inc News
JANX FAQ
What was Janux Therapeutics, Inc.’s price range in the past 12 months?
Janux Therapeutics, Inc. lowest stock price was $12.12 and its highest was $35.34 in the past 12 months.
What is Janux Therapeutics, Inc.’s market cap?
Janux Therapeutics, Inc.’s market cap is $1.02B.
When is Janux Therapeutics, Inc.’s upcoming earnings report date?
Janux Therapeutics, Inc.’s upcoming earnings report date is Nov 10, 2026 which is in 87 days.
How were Janux Therapeutics, Inc.’s earnings last quarter?
Janux Therapeutics, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.251 by -$0.099.
Is Janux Therapeutics, Inc. overvalued?
According to Wall Street analysts Janux Therapeutics, Inc.’s price is currently Undervalued.
Does Janux Therapeutics, Inc. pay dividends?
Janux Therapeutics, Inc. does not currently pay dividends.
What is Janux Therapeutics, Inc.’s EPS estimate?
Janux Therapeutics, Inc.’s EPS estimate is -0.47.
How many shares outstanding does Janux Therapeutics, Inc. have?
Janux Therapeutics, Inc. has 61,136,772 shares outstanding.
What happened to Janux Therapeutics, Inc.’s price movement after its last earnings report?
Janux Therapeutics, Inc. reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.251. Following the earnings report the stock price went down -1.553%.
Which hedge fund is a major shareholder of Janux Therapeutics, Inc.?
Currently, no hedge funds are holding shares in JANX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Janux Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.63 (132.39% Upside)
$35.63 (132.39% Upside)
Blogger Sentiment
Bullish
JANX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 289.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $85.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.97%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.38%
Trailing 12-Months
Company Description
Janux Therapeutics, Inc.
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
JANX Stock 12 Month Forecast
Average Price Target
$35.63
▲(132.39% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Vera Therapeutics
―
Biohaven Ltd.
―
Ownership Overview
19.89% Insiders
13.15% Mutual Funds
4.18% Other Institutional Investors
50.04% Public Companies and
Individual Investors